Akari Therapeutics Plc Stock Buy Hold or Sell Recommendation
| AKTX Stock | USD 1.21 0.09 8.04% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Akari Therapeutics PLC is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Akari Therapeutics PLC given historical horizon and risk tolerance towards Akari Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Akari Therapeutics PLC, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Akari Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Akari and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Akari |
Execute Akari Therapeutics Buy or Sell Advice
The Akari recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Akari Therapeutics PLC. Macroaxis does not own or have any residual interests in Akari Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Akari Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Akari Therapeutics Trading Alerts and Improvement Suggestions
| Akari Therapeutics generated a negative expected return over the last 90 days | |
| Akari Therapeutics has high historical volatility and very poor performance | |
| Akari Therapeutics may become a speculative penny stock | |
| Akari Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akari Therapeutics PLC currently holds about 8.15 M in cash with (16.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14. | |
| Akari Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio |
Akari Therapeutics Returns Distribution Density
The distribution of Akari Therapeutics' historical returns is an attempt to chart the uncertainty of Akari Therapeutics' future price movements. The chart of the probability distribution of Akari Therapeutics daily returns describes the distribution of returns around its average expected value. We use Akari Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Akari Therapeutics returns is essential to provide solid investment advice for Akari Therapeutics.
| Mean Return | -1.46 | Value At Risk | -12.59 | Potential Upside | 8.04 | Standard Deviation | 6.96 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Akari Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Akari Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Akari Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Akari Therapeutics PLC back and forth among themselves.
| Shares | Sabby Management Llc | 2024-06-30 | 0.0 | Truvestments Capital Llc | 2024-06-30 | 0.0 | Omnia Family Wealth, Llc | 2024-06-30 | 87.6 K | Citadel Advisors Llc | 2024-09-30 | 33.3 K | Hpm Partners Llc | 2024-06-30 | 23.6 K | Cresset Asset Management, Llc | 2024-09-30 | 18.4 K | Renaissance Technologies Corp | 2024-09-30 | 18.1 K | Susquehanna International Group, Llp | 2024-06-30 | 17.2 K | Ubs Group Ag | 2024-06-30 | 16 K | Bank Of America Corp | 2024-06-30 | 150 | Advisor Group Holdings, Inc. | 2024-06-30 | 100.0 |
Akari Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (236K) | 8.3M | (4.7M) | 3.9M | (9.4M) | (8.9M) | |
| Free Cash Flow | (12.3M) | (17.0M) | (18.8M) | (21.5M) | (16.4M) | (17.3M) | |
| Other Non Cash Items | 169K | 3.2M | 242.5K | (5.3M) | (7.6M) | (7.3M) | |
| Net Income | (24.8M) | (20.5M) | (17.4M) | (17.7M) | (10.0M) | (10.5M) | |
| End Period Cash Flow | 5.7M | 14.1M | 9.4M | 13.2M | 3.8M | 3.7M | |
| Change To Netincome | (1.7M) | 1.1M | 177.9K | 557.2K | 501.4K | 476.4K |
Akari Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Akari Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Akari Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Akari stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.42 | |
β | Beta against Dow Jones | -0.34 | |
σ | Overall volatility | 7.06 | |
Ir | Information ratio | -0.23 |
Akari Therapeutics Volatility Alert
Akari Therapeutics PLC is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Akari Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Akari Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Akari Therapeutics Fundamentals Vs Peers
Comparing Akari Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Akari Therapeutics' direct or indirect competition across all of the common fundamentals between Akari Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Akari Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Akari Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Akari Therapeutics to competition |
| Fundamentals | Akari Therapeutics | Peer Average |
| Return On Equity | -12.81 | -0.31 |
| Return On Asset | -1.73 | -0.14 |
| Current Valuation | 28.71 M | 16.62 B |
| Shares Outstanding | 20.65 M | 571.82 M |
| Shares Owned By Insiders | 11.90 % | 10.09 % |
| Shares Owned By Institutions | 0.50 % | 39.21 % |
| Number Of Shares Shorted | 22.55 K | 4.71 M |
| Price To Earning | (2.15) X | 28.72 X |
| Price To Book | 3.07 X | 9.51 X |
| EBITDA | (16.8 M) | 3.9 B |
| Net Income | (10.01 M) | 570.98 M |
| Cash And Equivalents | 8.15 M | 2.7 B |
| Cash Per Share | 0.14 X | 5.01 X |
| Total Debt | 4.58 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 3.73 X | 2.16 X |
| Book Value Per Share | (0.04) X | 1.93 K |
| Cash Flow From Operations | (16.43 M) | 971.22 M |
| Short Ratio | 1.92 X | 4.00 X |
| Earnings Per Share | (2.58) X | 3.12 X |
| Target Price | 80.0 | |
| Number Of Employees | 6 | 18.84 K |
| Beta | 0.95 | -0.15 |
| Market Capitalization | 30.35 M | 19.03 B |
| Total Asset | 4.36 M | 29.47 B |
| Retained Earnings | (227.46 M) | 9.33 B |
| Working Capital | 1.77 M | 1.48 B |
| Current Asset | 69.66 M | 9.34 B |
| Current Liabilities | 21.12 M | 7.9 B |
| Net Asset | 4.36 M |
Note: Insider Trading [view details]
Akari Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Akari . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Akari Therapeutics Buy or Sell Advice
When is the right time to buy or sell Akari Therapeutics PLC? Buying financial instruments such as Akari Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Akari Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.